The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Baseline liquid biopsy in combination with tissue biopsy to detect RAS mutations in mCRC
Sebastian Stintzing, MD, Charite University Hospital, Berlin, Germany, discusses the importance of liquid biopsy in combination tissue-based tests to detect RAS mutations in metastatic colorectal cancer (mCRC). Considering anti-EGFR only show efficacy in the RAS-wild type (WT) population, Prof. Stintzing emphasizes using liquid biopsy alongside a tissue test to reliably source out patients with RAS mutations who will not derive benefit form cetuximab or panitumumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
